Skip to content

Determining the Clinical Utility of Using Virtual Reality Headsets to Assess Visual Function in Those With Glaucoma.

Determining the Clinical Utility of Using Virtual Reality Headsets to Assess Visual Function in Those With Glaucoma.

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04273438
Enrollment
30
Registered
2020-02-18
Start date
2018-10-01
Completion date
2020-12-31
Last updated
2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma

Keywords

Perimetry, Virtual Reality, Visual field testing

Brief summary

To validate a new virtual reality (VR) based visual field test against the gold standard clinical perimetry test (Humphrey Visual field test 24-2).

Detailed description

Perimetry (or visual field testing) is a vision test used to evaluate a patient's peripheral vision. It involves a patient fixating on a central target and pressing a button when they see a spot of light in their peripheral vision. It is an important way of deciding whether Glaucoma is progressing or not. Next generation virtual reality (VR) technologies offer an exciting new way of conducting perimetry in either a clinical or home environment, allowing more affordable and more frequent monitoring of disease progression in glaucoma, and an easier and more comfortable experience for patients. The investigators propose to create a perimetry test using a commercially available head mounted display for VR, and to assess its accuracy in glaucoma patients in relation to standard automated perimetry.

Interventions

DEVICEVisual field testing using Oculus Rift and Humphrey Visual Field Perimeter

Glaucoma patients at Queen's University, Belfast, will be invited to undergo both Visual field testing using the Oculus Rift and the gold-standard Humphrey 24-2 (Carl Zeiss Meditec, Dublin, CA) at two visits, and evaluating consistency for detecting visual field impairments.

DEVICEVisual Field Testing using HUmphrey 24-3 Perimeter

Glaucoma patients at Queen's University, Belfast, will be invited to undergo both Visual field testing using the Oculus Rift and the gold-standard Humphrey 24-2 (Carl Zeiss Meditec, Dublin, CA) at two visits, and evaluating consistency for detecting visual field impairments.

Sponsors

University of Sussex
CollaboratorOTHER
Queen's University, Belfast
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

\- Patients with a clinical diagnosis of glaucoma with repeatable defects on standard automated perimetry.

Exclusion criteria

* Presence of other ocular disease which impacts vision such as age-related macular degeneration or diabetic retinopathy. * Any physical limitation that would make the participant unable to place their head in the head-rest to perform Humphrey Perimetry (Eg some patients with arthritic or neck problems are unable to use the headrests of ophthalmic devices). * Any cognitive impairment that would limit their ability to perform perimetry or a history of vertigo/dizziness.

Design outcomes

Primary

MeasureTime frameDescription
Pattern Standard DeviationAll statisitcal analysis will take place once all data collection has ended, average 1 year..Pattern standard deviation in decibels (dB), this is a standard summary measure generated by all perimetric tests and is considered to represent localised loss of visual function.
mean deviation (MD)All statisitcal analysis will take place once all data collection has ended, average 1 year..Mean deviation in decibels (dB), this is a standard summary measure generated by all perimetric tests and is considered to represent generalised loss of visual function.

Secondary

MeasureTime frameDescription
Repeatbility of both devicesAll statisitcal analysis will take place once all data collection has ended, average 1 year..Bland and Altman plots and intra-class correlation coefficients will be generated for both tests for visit 1 vs visit 2 data.

Countries

United Kingdom

Contacts

Primary ContactRuth Hogg, PhD
r.e.hogg@qub.ac.uk02890971654
Backup ContactLucie Dalton, BSc
l.dalton@qub.ac.uk

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026